Drug Trial Radar · NCT06516289
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
Last checked: Nov 20, 2026Latest source record: Dec 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Sep 30, 2024
Primary completion
Jun 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, open-label, multi-center, phase II clinical trial designed for HER2-negative breast cancer with pathogenic mutations in the germline gene (gBRCA1/2) that were indicated for neoadjuvant chemotherapy. The characteristics of this study are a precision treatment scheme without chemotherapy, the scheme of HRS-1167 combined with famitinib neoadjuvant therapy for patients with gBRCA mutations is explored, and the efficacy of combined immunotherapy is further explored according to the efficacy of the combination of the two drugs.
Conditions
- BRCA-Mutated Breast Carcinoma
- HER2-negative Breast Cancer
Interventions
HRS-1167Drug
a highly selective PARP1 inhibitor
FamitinibDrug
a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
CamrelizumabDrug
a humanised anti-programmed death-1 (anti PD-1) antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety run-in: Incidence rate of dose-limiting toxicities (DLTs)Time frame: 28±3 days
- Safety run-in: adverse events (AEs)Time frame: 28±3 days
- Safety run-in: Serious adverse events (SAEs)Time frame: 28±3 days
- Phase 2: Total Pathologic complete response (tpCR: ypT0/Tis ypN0) rateTime frame: Immediately after the surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Breast cancer institute of Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.